Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "Decreased body weight" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bariatric device and method
ActiveUS20100030017A1Effective and invasive mannerEffective and minimally invasiveSuture equipmentsDilatorsCardiac surfaceHeart Part
A bariatric device and method of causing weight loss in a recipient includes providing a bariatric device having an esophageal member, a cardiac member and a connector connected with the esophageal member and the cardiac member. The esophageal member has an esophageal surface that is configured to generally conform to the shape and size of a portion of the esophagus. The cardiac member has a cardiac surface that is configured to generally conform to the shape and size of a portion of the cardiac portion of the stomach. The esophageal surface is positioned at the esophagus. The cardiac surface is positioned at the cardiac portion of the stomach. The bariatric device stimulates receptors in order to influence a neurohormonal mechanism in the recipient.
Owner:BFKW
Bariatric device and method
ActiveUS8529431B2Effective and minimally invasiveEasy to move verticallySuture equipmentsDilatorsDecreased body weightNeurohormones
A bariatric device and method of causing weight loss in a recipient includes providing a bariatric device having an esophageal member, a cardiac member and a connector connected with the esophageal member and the cardiac member. The esophageal member has an esophageal surface that is configured to generally conform to the shape and size of a portion of the esophagus. The cardiac member has a cardiac surface that is configured to generally conform to the shape and size of a portion of the cardiac portion of the stomach. The esophageal surface is positioned at the esophagus. The cardiac surface is positioned at the cardiac portion of the stomach. The bariatric device stimulates receptors in order to influence a neurohormonal mechanism in the recipient.
Owner:BFKW
WSX receptor agonist antibodies
InactiveUS7524937B2Easy to implantFacilitates mobilizationPolypeptide with localisation/targeting motifCompound screeningDecreased body weightExtracellular Structure
Methods for identifying antibodies that decrease body weight, fat depot weight or food intake in an obese animal are provided, as well as antibodies. Preferred antibodies bind to a reactor having a WSX motif and the extracellular domain sequence within SEQ ID NO:2.
Owner:GENENTECH INC
Compositions and methods for inhibiting 5-alpha reductase
InactiveUS20050118282A1Lose weightModulate activityBiocideCosmetic preparationsBody organsDecreased body weight
Disclosed herein are compositions for controlling androgen activity in target organs and cells through the modulation of a 5-α-reductase activity. In certain aspects, these compositions are employed to modulate androgenic activity by inhibiting the formation and availability of active androgen in target cells. As a result, the present invention is directed toward the treatment of a wide variety of conditions including, but not limited to, the treatment of prostatic hyperplasia, prostatic cancer, hirsutism, acne, male pattern baldness, seborrhea, and other diseases related to androgen hyperactivity. Several of these compositions have been shown to effectively decrease body weight, and in some cases, to decrease the weight of an androgen-dependent body organ, such as the prostate and other organs.
Owner:APHIOS
Hsa-gdf-15 fusion polypeptide and use thereof
The disclosure relates to fusion polypeptides comprising serum albumin or a functional variant thereof and GDF15 protein or a functional variant thereof and to pharmaceutical compositions that contain the fusion polypeptides, nucleic acids that encode the fusion polypeptides, methods of making the polypeptides and use of the polypeptides to decreasing appetite, decreasing body weight and treating metabolic diseases.
Owner:NOVARTIS AG
Health coarse cereal food and preparation method thereof
InactiveCN105077041APromote hyperplasiaPrevent agglutinationFood preparationDecreased body weightPotato starch
The invention discloses health coarse cereal food and a preparation method thereof. The health coarse cereal food comprises the following raw materials in parts by weight: 35-37 parts of broad beans, 18-22 parts of fagopyrum tataricum, 7-9 parts of black tea powder, 10-13 parts of powder of radix puerariae, 9-11 parts of potato starch, 18-20 parts of beewax, 6-8 parts of turmeric powder, 7-11 parts of sesame oil, 9-12 parts of lentinus edodes, 4-6 parts of cummin seeds, 1-3 parts of cinnamon, 4-7 parts of alpinia officinarum, 12-14 parts of radix angelicae dahuricae, 6-8 parts of cardamom, 1-3 parts of amomum fruit, 6-11 parts of lysimachia sikokiana, 6-8 parts of hyssopus officinalis, 22-25 parts of soup-stock, 11-13 parts of radix polygoni multiflori and 21-25 parts of rheum palmatum. The coarse cereal health care food has comprehensive nutrition, lowers blood fat, blood glucose and blood pressure, decreases body weight, and strengthens brain.
Owner:ANHUI YANZHIFANG FOOD
Use of androstane derivatives for enhancing physical performance
InactiveUS20060234993A1Lose weightReduce appetiteOrganic active ingredientsGreek letter betaDecreased body weight
A method of decreasing body weight, reducing adipose tissue and reducing appetite in humans comprises administering a 5-Beta androstane derivative or a physiologically acceptable salt, ester or ether thereof of the general formula: wherein R3 is one of α-OH , β-OH, a mixture of α-OH and , β-OH, and O; and R7 is one of α-OH, β-OH and O.
Owner:INTELLECTUAL WELLNESS
Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
Infection with obesifying adenoviruses in animals and humans may be used to predict changes in body weight and disease status. More particularly, infection with certain adenoviruses, such as adenovirus type 36 (Ad-36) and adenovirus type 37 (Ad-37) may cause removal of the normal equilibrium factors that control fat cell metabolism and may make individuals more responsive than normal individuals to perturbations, which cause body composition change including weight gain or weight loss.
Owner:OBETECH LLC
Somatostatin agonists
InactiveUS20050164922A1Improve scalabilityImprove survivalBiocideAntiviralsDecreased body weightVIPoma
The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors. The peptides are useful for treating a variety of diseases, including Cushings Syndrome, gonadotropinoma, hyperparathyroidism, Paget's disease, VIPoma, nesidioblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea related to AIDS and other conditions, irritable bowel syndrome, pancreatitis, Crohn's Disease, systemic sclerosis, thyroid cancer, psoriasis, hypotension, panic attacks, sclerodoma, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Graves' Disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocysts, pancreatic ascites, leukemia, meningioma, cancer cachexia, acromegaly, restenosis, hepatoma, lung cancer, melanoma, inhibiting the accelerated growth of a solid tumor, decreasing body weight, treating insulin resistance, Syndrome X, prolonging the survival of pancreatic cells, fibrosis, hyperlipidemia, hyperamylinemia, hyperprolactinemia and prolactinemia.
Owner:SOC DE CONSEILS DE RECH
Use of DHEA derivatives for enhancing physical performance
ActiveUS20060241093A1Improve staminaLose weightCosmetic preparationsOrganic active ingredientsDecreased body weightMedicine
A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.
Owner:INTELLECTUAL WELLNESS
Method with nontherapeutic purpose for obtaining body weight reduction through discontinuous ketogenic diet
InactiveCN112335877ARelieve stressTake full advantage of weight lossFood scienceBiotechnologyAnimal science
The invention relates to the field of nutrient diets, in particular to a method with a nontherapeutic purpose for obtaining body weight reduction through a discontinuous ketogenic diet. The method forobtaining body weight reduction through the discontinuous ketogenic diet adopts a high-fat food composition and a ketogenic food composition as the diet. By use of an alternant mode of a high-fat diet and a ketogenic diet, the adverse effects of the high-fat diet and the ketogenic diet can be mutually offset, mental stress caused by long-term no ingestion of carbohydrates and intermittent fastingcan be alleviated, and meanwhile, the method can fully perform the weight reduction and fatty liver elimination functions of the ketogenic diet.
Owner:THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Composition for preventing, alleviating, or treating cachexia and muscle loss
ActiveUS20210052688A1Alleviate inappetenceReduce weight lossOrganic active ingredientsMuscular disorderMuscle lossPAEONIA Extract
The present disclosure relates to a composition containing a Paeoniae radix extract as an active ingredient. The composition may alleviate inappetence, weight loss, muscle loss and fatigue and inhibit hematopoietic toxicity. Thus, the composition may be effectively used for the prevention, alleviation or treatment of cachexia and muscle loss.
Owner:CHUNG ANG UNIV IND ACADEMIC COOP FOUND
Probiotic bacteria and regulation of fat storage
InactiveUS9113641B2Reduced uptakeExtended shelf lifeBiocideMilk preparationBacteroidesBifidobacterium
The present invention provides methods for manufacturing heat treated products involving the use of probiotic bacteria, e.g. lactic acid bacteria and / or Bifidobacteria, cultures of such bacteria, supernatant from such cultures, and / or concentrates of such supernatant and / or fractions of such supernatant. The invention further provides heat treated products of such processes and their use for regulation of cellular uptake of fat and / or triglycerides and / or body weight management or weight reduction and / or redistribution of fat and / or reduction in visceral and / or abdominal fat deposition in a subject.
Owner:ARLA FOODS AMBA
Compositions of fatostatin based heterocyclic compounds and uses thereof
ActiveUS20180000801A1Reduce body weightIncrease thermogenesisOrganic chemistryMetabolism disorderProliferative diseaseDrug
The present invention relates to compounds, pharmaceutical compositions and formulations that have a structure (I). The compounds comprise a heterocyclic ring where W, X, Y, and Z generally and independently are S, N or C with the proviso that at least 2 of these positions in the ring are other than carbon. A pyridine or a substituted pyridine A ring and a phenyl or a substituted phenyl B ring are covalently bonded to the heterocyclic ring. Further provided are methods for treating a metabolic disorder, cell proliferative disease, reducing body weight or increasing thermogenesis during weight loss with the compounds of structure as described or pharmaceutically acceptable salt or stereoisomer thereof or both.
Owner:FGH BIOTECH
Pharmaceutical compositions for combination therapy
ActiveUS9211271B2InhibitionRobust inhibitory efficacyMetabolism disorderHeterocyclic compound active ingredientsSide effectBody weight
Owner:SANIONA AS
Use of dhea derivatives for enhancing physical performance
ActiveUS20110245216A1Improve staminaLose weightCosmetic preparationsBiocideDecreased body weightEther
Owner:INTELLECTUAL WELLNESS
WSX receptor agonist antibodies
InactiveUS20060280737A1Easy to implantFacilitates mobilizationPolypeptide with localisation/targeting motifCompound screeningDecreased body weightExtracellular Structure
Methods for identifying antibodies that decrease body weight, fat depot weight or food intake in an obese animal are provided, as well as antibodies. Preferred antibodies bind to a reactor having a WSX motif and the extracellular domain sequence within SEQ ID NO:2.
Owner:GENENTECH INC
Novel glucocorticoid receptor ligands for the treatment of metabolic disorders
InactiveUS20070027117A1BiocidePhosphorous compound active ingredientsLipid formationDecreased body weight
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and / or decreasing body weight.
Owner:KARO BIO AB
Method of treatment
ActiveUS20200261392A1Reduce hungerReduced food intakeCosmetic preparationsDispersion deliveryDecreased body weightOligomer
The present invention provides a method of suppressing hunger by lowering plasma ghrelin levels comprising administration of a compound to a human or animal body, wherein the compound is selected from: (i) (R)-3-hydroxybutyrate; (ii) an ester of (R)-3-hydroxybutyrate; and (iii) an oligomer of (R)-3-hydroxybutyrate moieties; or a pharmaceutically acceptable salt or solvate thereof. The invention also provides a method of administering such a compound in a dosage effective to reduce hunger in order that a cosmetically beneficial loss or maintenance of body weight occurs, wherein in the method, plasma ghrelin levels are lowered. The aforementioned compound is also provided for use in a method of treatment of the human or animal body wherein the compound is administered and hunger is suppressed by lowering of plasma ghrelin levels. The compound is particularly useful for subjects having conditions associated with overeating, such as overweight, obese, severely obese patients or diabetic patients.
Owner:TDELTAS
Methods and compositions to reduce fat gain, promote weight loss in mammals
The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.
Owner:GATEWAY HEALTH ALLIANCES
Nutritional Compensation For Western-Type Diet
InactiveUS20130178530A1Increased HDL/LDL cholesterol ratioReduced VLDL-cholesterol levelBiocideMetabolism disorderDocosahexaenoic acidHigh fat high sugar
Disclosed is the use of a composition comprising docosahexaenoic acid (DHA) and / or arachidonic acid (ARA) in human subjects that are on the typical ‘Western-type” high-fat high-sugar diet. It was found, in a humanized animal model, that said composition is capable of compensating for one or more of the adverse health effects of said diet. Particularly, an effect was found in body weight reduction, without a lowering of food intake. The composition can be administered as an oral (pharmaceutical) dosage unit, as a nutritional supplement, or as a component in a food or drink.
Owner:MEAD JOHNSON NUTRITION
Glucocorticoid receptor ligands for the treatment of metabolic disorders
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and / or decreasing body weight.
Owner:KARO BIO AB
Glucocorticoid receptor ligands for the treatment of metabolic disorders
InactiveUS7141559B2Elevated glucocorticoid levelOrganic active ingredientsSteroidsLipid formationDecreased body weight
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and / or decreasing body weight.
Owner:KARO BIO AB
Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients
InactiveUS20140186473A1Reduce body weightReduce fatBiocideMetabolism disorderDecreased body weightBlood insulin
The present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a UCP of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance.
Owner:CJ CHEILJEDANG CORP +1
Compositions of fatostatin based heterocyclic compounds and uses thereof
The present invention relates to compounds, pharmaceutical compositions and formulations that have a structure (I). The compounds comprise a heterocyclic ring where W, X, Y, and Z generally and independently are S, N or C with the proviso that at least 2 of these positions in the ring are other than carbon. A pyridine or a substituted pyridine A ring and a phenyl or a substituted phenyl B ring are covalently bonded to the heterocyclic ring. Further provided are methods for treating a metabolic disorder, cell proliferative disease, reducing body weight or increasing thermogenesis during weight loss with the compounds of structure as described or pharmaceutically acceptable salt or stereoisomer thereof or both.
Owner:FGH BIOTECH
Method of treatment
PendingCN111132674AReduce intakeAvoid side effectsCosmetic preparationsDispersion deliveryHydroxybutyric acidDecreased body weight
The present invention provides a method of suppressing hunger by lowering plasma ghrelin levels comprising administration of a compound to a human or animal body, wherein the compound is selected from: (i) (R)-3-hydroxybutyrate; (ii) an ester of (R)-3-hydroxybutyrate; and (iii) an oligomer of (R)-3-hydroxybutyrate moieties; or a pharmaceutically acceptable salt or solvate thereof. The invention also provides a method of administering such a compound in a dosage effective to reduce hunger in order that a cosmetically beneficial loss or maintenance of body weight occurs, wherein in the method, plasma ghrelin levels are lowered. The aforementioned compound is also provided for use in a method of treatment of the human or animal body wherein the compound is administered and hunger is suppressed by lowering of plasma ghrelin levels. The compound is particularly useful for subjects having conditions associated with overeating, such as overweight, obese, severely obese patients or diabetic patients.
Owner:泰德尔塔有限公司
Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients
InactiveUS20170209511A1Prevent obesityLose weightMetabolism disorderMuscular disorderDecreased body weightBlood insulin
Owner:NEWTREE CO LTD
Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
PendingUS20220315633A1Inhibited food intakeReduced food intakePeptide/protein ingredientsAntibody mimetics/scaffoldsDecreased body weightPhysiology
The present invention is related to the fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein which function as GDF15 agonists. These GDF15 agonists may be useful in the treatment of obesity, reduction of body weight, decrease in food intake, or decrease of appetite.
Owner:JANSSEN PHARMA NV
Body weight load reduction device
A body weight unloading apparatus according to an aspect of the present invention includes a first actuator, a second actuator, a first support member, a second support member, a sensor for measuring the imbalance between floor reaction forces respectively acting on the legs of a user, and a control device for controlling operations of the actuators. One end of the support members is respectively connected to the actuators, and the other end of the support members is fitted to the user such that unloading forces that are supplied by the actuators respectively act on the legs of the user. The control device controls the actuators so as to respectively generate unloading forces determined according to the imbalance between the floor reaction forces.
Owner:ATR ADVANCED TELECOMM RES INST INT
Use of hydroxypregnenolone derivatives for enhancing health and physical performance
A method for the use of derivatives of hydroxypregnenolone (3-beta,17-alpha-dihydroxypregn-5-en-3-one) to enhance health and physical performance in humans and more particularly to the use of hydroxypregnenolone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function.
Owner:MARCHEWITZ ERIC D
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com